Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid
Jackson Center, PA, December 20, 2021 – Halberd Corporation (OTC PINK:HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Halberd has also completed confirmatory tests on the elimination of all the previously tested cytokines (see table below). Interleukin-2 is a pro-inflammatory cytokine whose role in Alzheimer’s Disease is not very well established. It may cause neurodegeneration as well as provide neuroprotection, depending on the level. Maintaining the appropriate level of IL-2, and other inflammatory cytokines in CSF is critical to neuro-health.
Dr. Mitchell S. Felder, Halberd’s Chief Technology Officer and a board certified attending neurologist stated, “The ability to precisely control the exact level of IL-2 in cerebrospinal fluid may be another important step in halting the progression of Alzheimer’s Disease; especially when this ability is combined with the precise control of the concentrations of phosphorylated- Tau, beta-Amyloid and other contributing inflammatory cytokines.”
William A. Hartman, Halberd Corporation’s Chairman, President & CEO, added, “The significance of these test results is that Halberd’s technology can be used to precisely control the levels of inflammatory cytokines and neurotransmitters to inhibit progression, and aid in the treatment, of various neurodegenerative diseases, such as Alzheimer’s, Lou Gehrig’s Disease, PTSD, CTE and epilepsy, among others. No other approach gives this kind of precise control.”
Hartman continued, “This tool has the potential to revolutionize medicine and the treatment of various neurologic and non-neurologic diseases and conditions. The potential of an effective treatment for Alzheimer’s, PTSD and CTE is a huge step forward for medicine.”
About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed nineteen related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.